Regenerative Medicines: a paradigm shift in healthcare. Spring 11By Michael Werner, Morrie Ruffin and Elizabeth West The regenerative medicine market offers phenomenal opportunities for growth in the next few decades. However, there are still major issues to be addressed to enable this nascent industry ...
|
The Post Genomic Era; what does it all mean? Spring 11By Dr Chris Torrance Information may no longer be a bottleneck to understanding and tackling complex genetic diseases such as cancer. For those who cut their research teeth not so very long ago, before PCR wa...
|
The future of molecular diagnostics for cancer. Spring 11By Dr Cliff Murray Drug Discovery The pharmaceutical industry is still struggling to cure cancer despite pouring enormous resources into the search for new treatments. We take a look at the some of the current technologie...
|
The Personalized Medicine Coalition. Spring 11The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption...
|
Protein biomarker immunoassays : opportunities and challenges Winter 10By Dr M. Walid Qoronfleh and Dr Klaus Lindpaintner With the biopharma industry under heavy pressure, transforming the scientific interchange between the laboratory and the clinic is exceedingly critical. Realising the costly toll of drug ...
|
THERANOSTICS an emerging tool in drug discovery and commercialisation. Fall 02By Dr Ian Gilham The increasing cost of healthcare along with new opportunities for improved treatments puts ever increasing pressures on healthcare budgets. In recent years the diagnostic industry in par...
|
Biomarkers make their mark on current research and drug development trends. Summer 10By Stéphane Parent and Dr Gregory Cosentino Biomarkers continue to become increasingly relevant in research and healthcare applications, as evidenced by the global market for products involved in their identification, validation, a...
|
Personalised medicine market and regulatory landscape. Summer 10By Dr Enal Razvi and Dr Patricia Hurley Over the past several years, there has been continuing interest in the deployment of personalised medicine via the development of companion diagnostics/therapeutics. The leading edge of t...
|
|
|
